

WISCONSIN DEPARTMENT OF SAFETY AND PROFESSIONAL SERVICES



Wisconsin Department of Safety and Professional Services Access to the Public Records of the Reports of Decisions

This Reports of Decisions document was retrieved from the Wisconsin Department of Safety and Professional Services website. These records are open to public view under Wisconsin's Open Records law, sections 19.31-19.39 Wisconsin Statutes.

Please read this agreement prior to viewing the Decision:

- The Reports of Decisions is designed to contain copies of all orders issued by credentialing authorities within the Department of Safety and Professional Services from November, 1998 to the present. In addition, many but not all orders for the time period between 1977 and November, 1998 are posted. Not all orders issued by a credentialing authority constitute a formal disciplinary action.
- Reports of Decisions contains information as it exists at a specific point in time in the Department of Safety and Professional Services data base. Because this data base changes constantly, the Department is not responsible for subsequent entries that update, correct or delete data. The Department is not responsible for notifying prior requesters of updates, modifications, corrections or deletions. All users have the responsibility to determine whether information obtained from this site is still accurate, current and complete.
- There may be discrepancies between the online copies and the original document. Original documents should be consulted as the definitive representation of the order's content. Copies of original orders may be obtained by mailing requests to the Department of Safety and Professional Services, PO Box 8935, Madison, WI 53708-8935. The Department charges copying fees. *All requests must cite the case number, the date of the order, and respondent's name* as it appears on the order.
- Reported decisions may have an appeal pending, and discipline may be stayed during the appeal. Information about the current status of a credential issued by the Department of Safety and Professional Services is shown on the Department's Web Site under "License Lookup."

The status of an appeal may be found on court access websites at:

<http://ccap.courts.state.wi.us/InternetCourtAccess> and <http://www.courts.state.wi.us/wscca>

- Records not open to public inspection by statute are not contained on this website.

By viewing this document, you have read the above and agree to the use of the Reports of Decisions subject to the above terms, and that you understand the limitations of this on-line database.

Correcting information on the DSPS website: An individual who believes that information on the website is inaccurate may contact DSPS@wisconsin.gov

STATE OF WISCONSIN
BEFORE THE BOARD OF NURSING

IN THE MATTER OF DISCIPLINARY
PROCEEDINGS AGAINST

LISA C. HOFSCHULZ, R.N., A.P.N.P.,
RESPONDENT.

:
:
:
:
:
:

FINAL DECISION AND ORDER

0005698

Division of Legal Services and Compliance Case No. 14 NUR 383

The parties to this action for the purpose of Wis. Stat. § 227.53 are:

Lisa C. Hofschulz, R.N., A.P.N.P.
6163 Washington Circle
Wauwatosa, WI 53213

Wisconsin Board of Nursing
P.O. Box 8366
Madison, WI 53708-8366

Division of Legal Services and Compliance
Department of Safety and Professional Services
P.O. Box 7190
Madison, WI 53707-7190

The parties in this matter agree to the terms and conditions of the attached Stipulation as the final disposition of this matter, subject to the approval of the Wisconsin Board of Nursing (Board). The Board has reviewed this Stipulation and considers it acceptable.

Accordingly, the Board in this matter adopts the attached Stipulation and makes the following Findings of Fact, Conclusions of Law and Order.

FINDINGS OF FACT

1. Respondent Lisa C. Hofschulz, R.N., A.P.N.P., (dob April 20, 1960) is licensed in the State of Wisconsin as a professional nurse, having license number 139392-30, first issued on October 5, 2001, and current through February 18, 2018.

2. Respondent is also certified by the State of Wisconsin as an advanced practice nurse prescriber, having certificate number 2399-33, first issued on March 2, 2004, and current through September 30, 2018.

3. Respondent's most recent address on file with the Wisconsin Department of Safety and Professional Services (Department) is 6163 Washington Circle, Wauwatosa, Wisconsin 53213.

4. Respondent was the co-owner and employed as an advanced practice nurse prescriber at a pain management clinic located in Wauwatosa, Wisconsin until November 14, 2014.

5. In November of 2014, Respondent left the previous pain management clinic and opened her own pain management practice, also located in Wauwatosa, Wisconsin.

6. Respondent collects a urine sample for a drug screen every month to evaluate underuse or overuse of narcotics. The results from the drug screens are part of the patient record.

Patient J.G.

7. On January 21, 2015, Patient J.G. (dob: January 19, 1986) presented to Respondent's clinic. On the January 21, 2015 visit notes, Respondent listed Patient J.G.'s diagnoses as right foot pain, right ankle surgery – post operation, bulging lumbar discs and lumbar back pain.

8. On January 21, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 120 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 10 mg tablets;
- c. 15 fentanyl 50 mcg patches; and
- d. 180 oxycodone 30 mg tablets.

9. On February 17, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for aminoclonazepam, which is a metabolite of clonazepam (non-prescribed);
- b. Positive for fentanyl (prescribed);
- c. Positive for oxycodone (prescribed);
- d. Positive for alprazolam (prescribed); and
- e. Positive for amphetamines (prescribed).

10. On February 17, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 90 alprazolam 2 mg tablets;
- b. 60 amphetamine salts 30 mg tablets;
- c. 15 fentanyl 75 mcg patches;
- d. 180 oxycodone 30 mg tablets; and
- e. 90 tizanidine 4 mg tablets.

11. On March 18, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Negative for amphetamine (prescribed);
- b. Positive for fentanyl (prescribed);
- c. Positive for oxycodone (prescribed); and
- d. Positive for alprazolam (prescribed).

12. On March 18, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.

13. On March 18, 2015, Respondent failed to document a plan of care.

14. On March 18, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 90 alprazolam 2 mg tablets;
- b. 60 amphetamine salts 30 mg tablets;
- c. 15 fentanyl 75 mcg patches;
- d. 180 oxycodone 30 mg tablets; and
- e. 90 ropinirole 0.5 mg tablets.

15. On April 15, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for norhydrocodone, which is a metabolite of hydrocodone (non-prescribed);
- b. Positive for aminoclonazepam, which is a metabolite of clonazepam (non-prescribed);
- c. Positive for fentanyl (prescribed);
- d. Positive for oxycodone (prescribed);
- e. Positive for alprazolam (prescribed); and
- f. Positive for amphetamine (prescribed).

16. On April 15, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.

17. On April 15, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 90 alprazolam 2 mg tablets;
- b. 60 amphetamine salts 30 mg tablets;
- c. 15 fentanyl 75 mcg patches;
- d. 180 oxycodone 30 mg tablets;
- e. 90 tizanidine 4 mg tablets;

- f. 90 ropinirole 0.5 mg tablets; and
- g. 30 sertraline 100 mg tablets.

18. On May 11, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for cocaine metabolite (non-prescribed/illicit);
- b. Positive for fentanyl (prescribed); and
- c. Positive for oxycodone (prescribed).

19. On May 12, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.

20. On May 12, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 90 alprazolam 2 mg tablets;
- b. 60 amphetamine salts 30 mg tablets;
- c. 15 fentanyl 75 mcg patches;
- d. 180 oxycodone 30 mg tablets;
- e. 90 tizanidine 4 mg tablets; and
- f. 90 ropinirole 0.5 mg tablets.

21. On June 9, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for cocaine metabolite (nonprescribed/illicit);
- b. Negative for amphetamines (prescribed);
- c. Positive for fentanyl (prescribed);
- d. Positive for oxycodone (prescribed); and
- e. Positive for alprazolam (prescribed).

22. On June 10, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.

23. On June 10, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 90 alprazolam 2 mg tablets;
- b. 60 amphetamine salts 30 mg tablets;
- c. 15 fentanyl 75 mcg patches; and
- d. 180 oxycodone 30 mg tablets.

24. On July 6, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for cocaine metabolite (non-prescribed/illicit);
 - b. Positive for alprazolam (prescribed);
 - c. Positive for 7-aminoclonazepam, which is a metabolite of clonazepam (non-prescribed);
 - d. Positive for fentanyl (prescribed);
 - e. Positive for oxycodone (prescribed)
 - f. Positive for amphetamines (prescribed); and
 - g. Positive for buprenorphine (non-prescribed).
25. On July 7, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.
26. On July 7, 2015, Respondent prescribed the following medications to Patient J.G.:
 - a. 90 alprazolam 2 mg tablets;
 - b. 60 amphetamine salts 30 mg tablets;
 - c. 15 fentanyl 75 mcg patches; and
 - d. 180 oxycodone 30 mg tablets.
27. On August 3, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:
 - a. Positive for cocaine metabolite (non-prescribed/illicit);
 - b. Positive for fentanyl (prescribed); and
 - c. Positive for oxycodone (prescribed).
28. On August 4, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.
29. On August 4, 2015, Respondent prescribed the following medications to Patient J.G.:
 - a. 120 alprazolam 1 mg tablets;
 - b. 60 amphetamine salts 30 mg tablets;
 - c. 15 fentanyl 75 mcg patches; and
 - d. 180 oxycodone 30 mg tablets.
30. On August 4, 2015, Respondent ordered a blood draw based on the positive cocaine screen. However, Patient J.G. did not have the blood draw completed until August 26, 2015.
31. Since the blood draw was taken 22 days after the original positive test, the cocaine would have metabolized out of Patient J.G.'s system.
32. On September 1, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for norhydrocodone, which is a metabolite of hydrocodone (non-prescribed);
- b. Negative for amphetamines (prescribed);
- c. Positive for fentanyl (prescribed);
- d. Positive for oxycodone (prescribed); and
- e. Positive for alprazolam (prescribed).

33. On September 1, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.

34. On September 1, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 90 alprazolam 1 mg tablets;
- b. 60 amphetamine salts 30 mg tablets;
- c. 15 fentanyl 75 mcg patches; and
- d. 180 oxycodone 30 mg tablets.

35. On September 29, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for hydrocodone (non-prescribed);
- b. Positive for hydromorphone (non-prescribed);
- c. Negative for amphetamines (prescribed);
- d. Positive for fentanyl (prescribed);
- e. Positive for oxycodone (prescribed); and
- f. Positive for alprazolam (prescribed).

36. On September 29, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.

37. On September 29, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 90 Klonopin® 1 mg tablets;
- b. 60 amphetamine salts 30 mg tablets;
- c. 15 fentanyl 75 mcg patches;
- d. 180 oxycodone 30 mg tablets; and
- e. 60 Lidoderm® 5% patches.

38. On October 27, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for hydrocodone (non-prescribed);
- b. Positive for hydromorphone (non-prescribed);

- c. Positive for lorazepam (non-prescribed);
- d. Positive for cocaine metabolite (non-prescribed/illicit);
- e. Positive for alprazolam (non-prescribed);
- f. Negative for amphetamines (prescribed); and
- g. Positive for oxycodone (prescribed).

39. On October 27, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.

40. On October 27, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 90 clonazepam 1 mg tablets;
- b. 60 amphetamine salts 30 mg tablets;
- c. 15 fentanyl 75 mcg patches; and
- d. 180 oxycodone 30 mg tablets.

41. On October 27, 2015, Respondent also ordered a blood draw due to the positive drug screen for an illicit drug.

42. There are no results from the ordered blood draw in Patient J.G.'s medical record.

43. On November 23, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for alprazolam (non-prescribed);
- b. Positive for lorazepam (non-prescribed);
- c. Negative for amphetamines (prescribed);
- d. Positive for fentanyl (prescribed);
- e. Positive for oxycodone (prescribed); and
- f. Positive for 7-aminoclonazepam, which is a metabolite of clonazepam (prescribed).

44. On November 24, 2015, Respondent failed to take and/or document Patient J.G.'s vital signs.

45. On November 24, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 60 amphetamine salts 30 mg tablets;
- b. 90 clonazepam 1 mg tablets;
- c. 15 fentanyl 100 mcg patches; and
- d. 180 oxycodone 30 mg tablets.

46. On December 21, 2015, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for alprazolam (non-prescribed);
- b. Positive for lorazepam (non-prescribed);
- c. Negative for amphetamines (prescribed);
- d. Positive for fentanyl (prescribed);
- e. Positive for oxycodone (prescribed); and
- f. Positive for 7-aminoclonazepam, which is a metabolite of clonazepam (prescribed).

47. On December 22, 2015, Respondent prescribed the following medications to Patient J.G.:

- a. 60 amphetamine salts 30 mg tablets;
- b. 90 clonazepam 1 mg tablets;
- c. 15 fentanyl 100 mcg patches;
- d. 180 oxycodone 30 mg tablets;
- e. 90 tizanidine 4 mg tablets; and
- f. 30 Lidoderm 5% patches.

48. On January 21, 2016, another provider at the clinic prescribed medications for Patient J.G.

49. On February 16, 2016, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for fentanyl (prescribed);
- b. Positive for oxycodone (prescribed);
- c. Positive for 7-aminoclonazepam, which is a metabolite of clonazepam (prescribed); and
- d. Positive for amphetamines (prescribed).

50. On February 16, 2016, Respondent prescribed the following medications to Patient J.G.:

- a. 60 amphetamine salts 30 mg tablets;
- b. 90 clonazepam 1 mg tablets;
- c. 15 fentanyl 100 mcg patches; and
- d. 180 oxycodone 30 mg tablets.

51. On March 14, 2016, Patient J.G. submitted a urine sample to be drug tested. Patient J.G.'s test results were as follows:

- a. Positive for alprazolam (non-prescribed);
- b. Positive for lorazepam (non-prescribed);
- c. Positive for fentanyl (prescribed);
- d. Positive for oxycodone (prescribed);

- e. Negative for amphetamines (prescribed); and
- f. Positive for 7-aminoclonazepam, which is a metabolite of clonazepam (prescribed).

52. On March 14, 2016, Respondent prescribed the following medications to Patient J.G.:

- a. 90 clonazepam 1 mg tablets;
- b. 15 fentanyl 75 mcg patches;
- c. 180 oxycodone 30 mg tablets; and
- d. tizanidine 4 mg tablets.

53. By continuing to prescribe medications to Patient J.G. despite instances when Patient J.G. was testing positive for illegal substances, testing negative for substances she was prescribed or testing positive for substances she was not prescribed, Respondent fell below the minimum standard of care.

54. Respondent fell below the standard of care by failing to put a strategy in place to mitigate Patient J.G.'s noncompliance.

55. Respondent's documentation in Patient J.G.'s chart fell below the minimum standard of care by failing to document the following:

- a. Educating Patient J.G. on the importance of taking only the medication she was prescribed;
- b. Educating Patient J.G. on the importance of taking all the medications Patient J.G. was prescribed;
- c. Educating Patient J.G. on the importance of not using illicit drugs;
- d. Informing Patient J.G. that failing to comply with treatment would result in discharge from patient care;
- e. A plan of care; and/or,
- f. Vital signs due to potential complications that can arise with the medications Patient J.G. was prescribed, including but not limited to respiratory depression.

Patient A.S.

56. On December 30, 2014, Patient A.S. (dob: January 2, 1989) presented to Respondent's clinic. On the December 30, 2014 visit notes, Respondent listed Patient A.S.'s diagnoses as lumbar back pain, bilateral leg pain, bilateral foot pain, neuropathy in her feet and hepatic cysts.

57. On January 28, 2015, Respondent prescribed the following medications to Patient A.S.:

- a. 90 methadone 10 mg tablets;
- b. 120 oxycodone 30 mg tablets; and
- c. 30 Ambien® 10 mg tablets.

58. On February 26, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:

- a. Negative for zolpidem (prescribed);
- b. Positive for methadone (prescribed); and
- c. Positive for oxycodone (prescribed).

59. On February 26, 2015, Respondent prescribed the following medications to Patient A.S.:

- a. 90 methadone 10 mg tablets;
- b. 120 oxycodone 30 mg tablets; and
- c. 30 Ambien® 10 mg tablets.

60. On March 26, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:

- a. Positive for aminoclonazepam, which is a metabolite of clonazepam (non-prescribed);
- b. Negative for zolpidem (prescribed);
- c. Positive for methadone (prescribed); and
- d. Positive for oxycodone (prescribed).

61. On March 26, 2015, Respondent failed to take and/or document Patient A.S.'s vital signs.

62. On March 26, 2015, Respondent prescribed the following medications to Patient A.S.:

- a. 60 clonazepam 1 mg tablets;
- b. 90 methadone 10 mg tablets;
- c. 150 oxycodone 30 mg tablets; and
- d. 30 Ambien® 10 mg tablets.

63. On April 22, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:

- a. Negative for zolpidem (prescribed);
- b. Positive for methadone (prescribed);
- c. Positive for oxycodone (prescribed); and

- d. Positive for 7-aminoclonazepam, which is a metabolite of clonazepam (prescribed).
64. On April 23, 2015, Respondent failed to take and/or document Patient A.S.'s vital signs.
65. On April 23, 2015, Respondent prescribed the following medications to Patient A.S.:
- a. 60 clonazepam 1 mg tablets;
 - b. 90 methadone 10 mg tablets;
 - c. 150 oxycodone 30 mg tablets; and
 - d. 30 Ambien® 10 mg tablets.
66. On May 17, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:
- a. Negative for zolpidem (prescribed);
 - b. Positive for 7-aminoclonazepam, which is a metabolite of clonazepam (prescribed);
 - c. Positive for methadone (prescribed); and
 - d. Positive for oxycodone (prescribed).
67. On May 18, 2015, Respondent failed to take and/or document Patient A.S.'s vital signs.
68. On May 18, 2015, Respondent prescribed the following medications to Patient A.S.:
- a. 60 clonazepam 1 mg tablets;
 - b. 90 methadone 10 mg tablets;
 - c. 150 oxycodone 30 mg tablets; and
 - d. 30 Ambien® 10 mg tablets.
69. On June 14, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:
- a. Positive for hydromorphone (non-prescribed);
 - b. Positive for morphine (non-prescribed);
 - c. Positive for amphetamines (non-prescribed);
 - d. Negative for zolpidem (prescribed);
 - e. Positive for alcohol;
 - f. Positive for clonazepam (prescribed);
 - g. Positive for methadone (prescribed); and
 - h. Positive for oxycodone (prescribed).

70. On June 15, 2015, Respondent failed to take and/or document Patient A.S.'s vital signs.
71. On June 15, 2015, Respondent prescribed the following medications to Patient A.S.:
- 60 clonazepam 1 mg tablets;
 - 150 methadone 10 mg tablets;
 - 150 oxycodone 30 mg tablets; and
 - 30 Ambien® 10 mg tablets.
72. On July 9, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:
- Positive for alprazolam (non-prescribed);
 - Positive for amphetamines (non-prescribed);
 - Negative for clonazepam (prescribed);
 - Positive for methadone (prescribed);
 - Positive for oxycodone (prescribed); and
 - Positive for zolpidem (prescribed).
73. On July 10, 2015, Respondent failed to take and/or document Patient A.S.'s vital signs.
74. On July 10, 2015, Respondent prescribed the following medications to Patient A.S.:
- 150 methadone 10 mg tablets;
 - 150 oxycodone 30 mg tablets; and
 - 30 Ambien® 10 mg tablets.
75. On August 9, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:
- Positive for amphetamines (non-prescribed);
 - Negative for zolpidem (prescribed);
 - Positive for methadone (prescribed);
 - Positive for oxycodone (prescribed); and
 - Positive for 7-aminoclonazepam, which is a metabolite of clonazepam, (non-prescribed).
76. On August 10, 2015, Respondent failed to take and/or document Patient A.S.'s vital signs.
77. On August 10, 2015, Respondent prescribed the following medications to Patient A.S.:
- 150 methadone 10 mg tablets;

- b. 180 oxycodone 30 mg tablets; and
- c. 30 Ambien® 10 mg tablets.

78. On September 9, 2015, Respondent prescribed the following medications to Patient A.S.:

- a. 60 clonazepam 1 mg tablets;
- b. 150 methadone 10 mg tablets; and
- c. 180 oxycodone 30 mg tablets.

79. On September 9, 2015, Respondent failed to take and/or document Patient A.S.'s vital signs.

80. On September 9, 2015, Respondent failed to document a plan of care for Patient A.S.

81. On September 10, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:

- a. Positive for EDDP, the metabolite for methadone (prescribed);
- b. Positive for oxycodone (prescribed); and
- c. Positive for 7-aminoclonazepam, which is a metabolite of clonazepam (prescribed).

82. On October 5, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:

- a. Positive for oxycodone (prescribed);
- b. Positive for EDDP, the metabolite for methadone (prescribed); and
- c. Positive for 7-aminoclonazepam, which is a metabolite of clonazepam (prescribed).

83. On October 5, 2015, Respondent failed to take and/or document Patient A.S.'s vital signs.

84. On October 5, 2015, Respondent prescribed the following medications to Patient A.S.:

- a. 150 methadone 10 mg tablets;
- b. 180 oxycodone 30 mg tablets; and
- c. 30 Ambien® 10 mg tablets.

85. On November 2, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:

- a. Positive for alprazolam (non-prescribed);
- b. Positive for amphetamines (non-prescribed);
- c. Positive for methadone (prescribed);

- d. Positive for oxycodone (prescribed); and
- e. Positive for alcohol.

86. On November 2, 2015, Respondent prescribed the following medications to Patient A.S.:

- a. 60 clonazepam 1 mg tablets;
- b. 150 methadone 10 mg tablets; and
- c. 180 oxycodone 30 mg tablets.

87. On December 1, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:

- a. Positive for noroxycodone, which is the metabolite of oxycodone (prescribed);
- b. Positive for methadone (prescribed); and
- c. Positive for amphetamine (non-prescribed).

88. On December 1, 2015, Respondent failed to take and/or document Patient A.S.'s vital signs.

89. On December 1, 2015, Respondent prescribed the following medications to Patient A.S.:

- a. 60 clonazepam 1 mg tablets;
- b. 150 methadone 10 mg tablets;
- c. 180 oxycodone 30 mg tablets; and
- d. 30 Ambien® 10 mg tablets.

90. On December 29, 2015, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:

- a. Positive for oxycodone (prescribed);
- b. Positive for methadone (prescribed);
- c. Positive for alprazolam (non-prescribed); and
- d. Positive for amphetamines (non-prescribed).

91. On December 29, 2015, Respondent prescribed the following medications to Patient A.S.:

- a. 60 clonazepam 1 mg tablets;
- b. 150 methadone 10 mg tablets; and
- c. 180 oxycodone 30 mg tablets.

92. On January 26, 2016, Patient A.S. submitted a urine sample to be drug tested. Patient A.S.'s test results were as follows:

- a. Positive for alprazolam (non-prescribed);
- b. Positive for hydromorphone (non-prescribed);
- c. Positive for morphine (non-prescribed);
- d. Positive for amphetamines (non-prescribed);
- e. Positive for 6-acetylmorphine, the metabolite for heroin (non-prescribed/illicit);
- f. Positive for oxycodone (prescribed); and
- g. Positive for methadone (prescribed).

93. On the January 26, 2016 drug screen, Respondent documented that if Patient A.S. tested positive for heroin again, she would be discharged from patient care.

94. Patient A.S. was not discharged from patient care in January of 2016.

95. By continuing to prescribe medications to Patient A.S. despite instances of Patient A.S. testing positive for illegal substances, testing negative for substances she was prescribed or testing positive for substances she was not prescribed, Respondent fell below the minimum standard of care.

96. Respondent fell below the standard of care by failing to put a strategy in place to mitigate Patient A.S.'s noncompliance.

97. Respondent's documentation in Patient A.S.'s chart falls below the minimum standard of care by failing to document the following:

- a. Educating Patient A.S. on the importance of taking only the medication she was prescribed;
- b. Educating Patient A.S. on the importance of taking all medications Patient A.S. was prescribed;
- c. Educating Patient A.S. on the importance of abstaining from alcohol use while taking her prescribed medications;
- d. Educating Patient A.S. on the importance of not using illicit drugs;
- e. Informing Patient A.S. that failing to comply with treatment would result in discharge from patient care;
- f. A plan of care for Patient A.S.; and/or
- g. Vital signs due to potential complications that can arise with the medications Patient A.S. was prescribed; including, but not limited to, respiratory depression.

Patient D.B.

98. On December 30, 2014, Patient D.B. (dob: May 6, 1976) presented to Respondent's clinic. On the December 30, 2014 visit notes, Respondent listed Patient D.B.'s diagnoses as lumbar back pain, bulging disc disease, lumbar tumor growth and two hernias in the abdomen.

99. On December 30, 2014, Respondent prescribed the following medications to Patient D.B.:

- a. 60 Xanax® 2 mg tablets;
- b. 150 oxycodone 30 mg tablets;
- c. 60 OxyContin® 80 mg tablets; and
- d. 90 tizanidine 4 mg tablets.

100. On January 28, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for oxycodone (prescribed);
- b. Negative for alprazolam (prescribed); and
- c. Positive for amphetamines (non-prescribed).

101. On January 28, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 Xanax® 2 mg tablets;
- b. 150 oxycodone 30 mg tablets;
- c. 60 OxyContin® 80 mg tablets; and
- d. 90 tizanidine 4 mg tablets.

102. On February 10, 2015, Respondent prescribed the following medication to Patient D.B.:

- a. 90 amphetamine salts 30 mg tablets.

103. On February 27, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Positive for amphetamines (prescribed); and
- c. Positive for oxycodone (prescribed).

104. On March 27, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Positive for benzoylecgonine, the metabolite for cocaine (non-prescribed/illicit);

- c. Positive for amphetamine (prescribed);
- d. Positive methadone (non-prescribed); and
- e. Positive for oxycodone (prescribed).

105. On March 27, 2015, Respondent failed to document any visit notes.

106. On March 27, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;
- c. 180 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

107. On April 23, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Negative for amphetamines (prescribed); and
- c. Positive for oxycodone (prescribed).

108. On April 23 and/or 24, 2015, Respondent failed to document any visit notes.

109. On April 24, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;
- c. 180 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

110. On May 17, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Positive for oxycodone (prescribed); and
- b. Positive for amphetamines (prescribed).

111. On May 17 and/or 18, 2015, Respondent failed to document any patient visit notes.

112. On May 18, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;
- c. 180 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

113. On June 17, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Positive for oxycodone (prescribed); and
- c. Positive for amphetamines (prescribed).

114. On June 17 and/or 18, 2015, Respondent failed to document any patient visit notes.

115. On June 18, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;
- c. 180 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

116. On July 6, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 120 oxycodone 20 mg tablets; and
- b. 60 oxycodone 30 mg tablets.

117. On July 13, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Positive for oxycodone (prescribed); and
- c. Positive for amphetamines (prescribed).

118. On July 14, 2015, Respondent failed to take and/or document Patient D.B.'s vital signs.

119. On July 16, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;
- c. 180 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

120. On August 5, 2015, Respondent prescribed the following medication to Patient D.B.:

- a. 90 amphetamine salts 30 mg.

121. On August 17, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Negative for amphetamines (prescribed); and
- c. Positive for oxycodone (prescribed).

122. On August 18, 2015, Respondent failed to take and/or document Patient D.B.'s vital signs.

123. On August 18, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;
- c. 180 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

124. On September 14, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Positive for morphine (non-prescribed);
- c. Positive for oxycodone (prescribed); and
- d. Positive for amphetamines (prescribed).

125. On September 14, 2015, Respondent failed to take and/or document Patient D.B.'s vital signs.

126. On September 14, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;
- c. 210 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

127. On October 12, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Positive for oxycodone (prescribed); and
- c. Positive for amphetamines (prescribed).

128. On October 12, 2015, Respondent failed to take and/or document Patient D.B.'s vital signs.

129. On October 12, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 90 amphetamine salts 30 mg tablets;
- b. 210 oxycodone 30 mg tablets; and
- c. 60 OxyContin® 80 mg tablets.

130. On November 9, 2015, Patient D.B. submitted to a drug screen and tested positive for all of his prescribed medications.

131. On November 9, 2015, Respondent failed to take and/or document Patient D.B.'s vital signs.

132. On November 9, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;
- c. 210 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

133. On December 7, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Positive for oxycodone (prescribed); and
- c. Positive for amphetamines (prescribed).

134. On December 7, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;
- c. 210 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

135. On December 30, 2015, Patient D.B. submitted a urine sample to be drug tested. Patient D.B.'s test results were as follows:

- a. Negative for alprazolam (prescribed);
- b. Positive for oxycodone (prescribed); and
- c. Positive for amphetamines (prescribed).

136. On December 30, 2015, Respondent prescribed the following medications to Patient D.B.:

- a. 60 alprazolam 1 mg tablets;
- b. 90 amphetamine salts 30 mg tablets;

- c. 210 oxycodone 30 mg tablets; and
- d. 60 OxyContin® 80 mg tablets.

137. By continuing to prescribe medications to Patient D.B. despite instances of Patient D.B. testing positive for illegal substances, testing negative for substances he was prescribed or testing positive for substances he was not prescribed, Respondent fell below the minimum standard of care for prescribing.

138. Respondent fell below the standard of care by failing to put a strategy in place to mitigate Patient D.B.'s noncompliance.

139. Respondent's documentation in Patient D.B.'s chart fell below the minimum standard of care by failing to document:

- a. Educating Patient D.B. on the importance of taking only the medication he was prescribed;
- b. Educating Patient D.B. on the importance of taking all the medications Patient D.B. was prescribed;
- c. Educating Patient D.B. on the importance of not using illicit drugs;
- d. Informing Patient D.B. that failing to comply with the treatment would result in discharge from patient care;
- e. Entire visit notes; and/or
- f. Vital signs due to potential complications that can arise with the medications Patient D.B. was prescribed; including, but not limited to, respiratory depression.

Patient J.C.

140. On February 2, 2015, Patient J.C. (dob: September 4, 1964) presented to Respondent's clinic. On February 2, 2015, Respondent documented that Patient J.C. was diagnosed with lumbar back pain, left hip pain, bilateral foot pain and muscle spasms.

141. On February 2, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 150 methadone 10 mg tablets; and
- b. 150 oxycodone 30 mg tablets.

142. On March 2, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Negative for methadone (prescribed); and
- b. Positive for oxycodone (prescribed).

143. On March 2, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 150 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

144. On March 31, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Negative for methadone (prescribed); and
- b. Positive for oxycodone (prescribed).

145. On March 30, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 150 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

146. On April 26, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Negative for methadone (prescribed); and
- b. Positive for oxycodone (prescribed).

147. On April 27, 2015, Respondent failed to take and/or document Patient J.C.'s vital signs.

148. On April 27, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 150 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

149. On May 25, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Positive for methadone (prescribed); and
- b. Negative for oxycodone (prescribed).

150. On May 26, 2015, Respondent failed to take and/or document Patient J.C.'s vital signs.

151. On May 26, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 150 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

152. On June 21, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Negative for methadone (prescribed); and
- b. Positive for oxycodone (prescribed).

153. On June 22, 2015, Respondent failed to take and/or document Patient J.C.'s vital signs.

154. On June 22, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 150 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

155. On July 26, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Negative for methadone (prescribed); and
- b. Positive for oxycodone (prescribed).

156. On July 26 and/or 27, 2015, Respondent failed to document any patient visit notes.

157. On July 27, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 180 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

158. On August 23, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Negative for methadone (prescribed); and
- b. Positive for oxycodone (prescribed).

159. On August 24, 2015, Respondent failed to take and/or document Patient J.C.'s vital signs.

160. On August 24, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 180 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

161. On September 21, 2015, there is no documented drug screen.

162. On September 21, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 180 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

163. On October 19, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Negative for methadone (prescribed); and
- b. Positive for oxycodone (prescribed).

164. On October 19, 2015, Respondent failed to take and/or document Patient J.C.'s vital signs.

165. On October 19, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 180 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

166. On November 16, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Negative for methadone (prescribed); and
- b. Positive for oxycodone (prescribed).

167. On November 16, 2015, Respondent failed to take and/or document Patient J.C.'s vital signs.

168. On November 16, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 180 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

169. On December 14, 2015, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Positive for methadone (prescribed); and
- b. Negative for oxycodone (prescribed).

170. On December 14, 2015, Respondent prescribed the following medications to Patient J.C.:

- a. 180 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

171. On January 11, 2016, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Positive for methadone (prescribed); and
- b. Negative for oxycodone (prescribed).

172. On January 11, 2016, Respondent prescribed the following medications to Patient J.C.:

- a. 180 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

173. On January 20, 2016, Patient J.C. was called for a pill count. The patient record reflects that the patient was out of town in Texas and the rest of the pill count form was left incomplete.

174. On February 8, 2016, Patient J.C. submitted a urine sample to be drug tested. Patient J.C.'s test results were as follows:

- a. Positive for methadone (prescribed);
- b. Positive for oxycodone (prescribed); and
- c. Positive for alcohol.

175. On February 8, 2016, Respondent prescribed the following medications to Patient J.C.:

- a. 180 methadone 10 mg tablets; and
- b. 180 oxycodone 30 mg tablets.

176. By continuing to prescribe medications to Patient J.C. despite instances of Patient J.C. testing negative for substances she was prescribed, Respondent fell below the minimum standard of care.

177. Respondent fell below the standard of care by failing to put a strategy in place to mitigate Patient J.C.'s noncompliance.

178. Respondent's documentation in Patient J.C.'s chart fell below the minimum standard of care by failing to document:

- a. Educating Patient J.C. on the importance of taking all medications Patient J.C. was prescribed;
- b. Educating Patient J.C. on the importance of abstaining from alcohol use while taking her prescribed medications;
- c. Informing Patient J.C. that failing to comply with treatment would result in discharge from patient care;

- d. Vital signs due to potential complications that can arise with the medications Patient J.C. was prescribed; including, but not limited to, respiratory depression; and/or
- e. An entire visit note.

179. During the Department investigation, Respondent took fifteen (15) hours of education on the topics of chronic pain syndromes: current concepts and treatment strategies, fifteen (15) additional credits on the topic of prescription opioids: risk management and strategies for safe use and five (5) hours of education on the topic of documentation. Respondent provided proof of successful completion of this education to the Department.

180. Respondent is no longer practicing in Wisconsin.

181. In resolution of this matter, Respondent consents to the entry of the following Conclusions of Law and Order.

CONCLUSIONS OF LAW

1. The Wisconsin Board of Nursing has jurisdiction to act in this matter pursuant to Wis. Stat. § 441.07, and is authorized to enter into the attached Stipulation pursuant to Wis. Stat. § 227.44(5).

2. Pursuant to Wis. Stat. § 961.20(2)(a), alprazolam is a schedule IV controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(3).

3. Pursuant to Wis. Stat. § 961.16(5)(a), an amphetamine is a schedule II controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(2).

4. Pursuant to Wis. Stat. § 961.16(3)(f), fentanyl is a schedule II controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(2).

5. OxyContin® is a form of oxycodone. Pursuant to Wis. Stat. § 961.16(2)(a)11., oxycodone is a schedule II controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(2).

6. Pursuant to Wis. Stat. § 961.16(2)(a)11., oxycodone is a schedule II controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(2).

7. Pursuant to Wis. Stat. § 961.20(2)(cn), clonazepam is a schedule IV controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(3).

8. Pursuant to Wis. Stat. § 961.16(2)(a)7., hydrocodone is a schedule II controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(2).

9. Pursuant to Wis. Stat. § 961.16(2)(a)8., hydromorphone is a schedule II controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(2).

10. Pursuant to Wis. Stat. § 961.20(2)(er), lorazepam is a schedule IV controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(3).

11. Pursuant to Wis. Stat. § 961.20(2)(p), zolpidem is a schedule IV controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(3).

12. Pursuant to Wis. Stat. § 961.20(2)(n), temazepam is a schedule IV controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(3).

13. Pursuant to Wis. Stat. § 961.16(5)(d), methylphenidate is a schedule II controlled substance for which, under the circumstances at issue, a prescription is required pursuant to Wis. Stat. § 961.38(2).

14. By the conduct described in the Findings of Fact, Lisa C. Hofschulz, R.N., A.P.N.P., engaged in unprofessional conduct as defined by Wis. Admin. Code § N 7.03(6)(a), by failing to perform nursing with reasonable skill and safety.

15. By the conduct described in the Findings of Fact, Lisa C. Hofschulz, R.N., A.P.N.P., engaged in unprofessional conduct as defined by Wis. Admin. Code § N 7.03(6)(c), by departing from or failing to conform to the minimal standards of acceptable nursing practice that may create unnecessary risk or danger to a patient's life, health, or safety.

16. As a result of the above conduct, Lisa C. Hofschulz, R.N., A.P.N.P., is subject to discipline pursuant to Wis. Stat. § 441.07(1g)(b) and (d).

ORDER

1. The attached Stipulation is accepted.

2. The professional nursing license and advanced practice nurse prescriber certificate of Lisa C. Hofschulz, R.N., A.P.N.P., (license number 139392-30 and certificate number 2399-33) to practice nursing in the State of Wisconsin, her privilege to practice in Wisconsin pursuant to the Nurse Licensure Compact and her privilege to practice in Wisconsin pursuant to the Enhanced Nurse Licensure Compact, are **SUSPENDED** for twenty-one (21) days from the date of this Order.

3. The professional nursing license and advanced practice nurse prescriber certificate of Lisa C. Hofschulz, R.N., A.P.N.P., (license number 139392-30 and certificate number 2399-33) to practice nursing in the State of Wisconsin, her privilege to practice in Wisconsin pursuant to the Nurse Licensure Compact and her privilege to practice in Wisconsin pursuant to the Enhanced Nurse Licensure Compact, are LIMITED as follows:

- a. Respondent shall not practice pain management.
- b. Respondent shall not return to practice in the State of Wisconsin unless she provides written notification to the Board, or its designee, of intent to return to Wisconsin at least fifteen (15) days prior to return.
- c. If Respondent notifies the Board of her intent to return to practice in the State of Wisconsin, the Board, or its designee, may impose additional limitations upon Respondent's license.

4. Pursuant to Uniform Nurse Licensure Compact and Enhanced Nurse Licensure Compact regulations, Respondent's nursing practice is limited to Wisconsin during the pendency of these limitations. This requirement may be waived only upon the prior written authorization of both the Wisconsin Board of Nursing and the regulatory board in the state in which Respondent proposes to practice.

5. Within one (1) year from the date of this Order, Respondent shall pay COSTS of this matter in the amount of \$10,000.00.


6. Any documents, requests, reports, proof of successful completion of the ordered education and payment of costs (made payable to the Wisconsin Department of Safety and Professional Services) shall be sent by Respondent to the Department Monitor at the address below:

Department Monitor
Division of Legal Services and Compliance
Department of Safety and Professional Services
P.O. Box 7190, Madison, WI 53707-7190
Telephone (608) 267-3817; Fax (608) 266-2264
DSPSMonitoring@wisconsin.gov

7. In the event Respondent violates any term of this Order, Respondent's license (139392-30) and certificate (2399-33), or Respondent's right to renew her license, may, in the discretion of the Board or its designee, be SUSPENDED, without further notice or hearing, until Respondent has complied with the terms of the Order. The Board may, in addition and/or in the alternative refer any violation of this Order to the Division of Legal Services and Compliance for further investigation and action.

8. This Order is effective on the date of its signing.

WISCONSIN BOARD OF NURSING

by: 
A Member of the Board

4-12-18
Date

STATE OF WISCONSIN
BEFORE THE BOARD OF NURSING

IN THE MATTER OF DISCIPLINARY
PROCEEDINGS AGAINST

LISA C. HOFSCHULZ, R.N., A.P.N.P.,
RESPONDENT.

:
:
:
:
:
:

STIPULATION

0005698

Division of Legal Services and Compliance Case No. 14 NUR 383

Respondent Lisa C. Hofschulz, R.N., A.P.N.P., and the Division of Legal Services and Compliance, Department of Safety and Professional Services stipulate as follows:

1. This Stipulation is entered into as a result of a pending investigation by the Division of Legal Services and Compliance. Respondent consents to the resolution of this investigation by Stipulation.

2. Respondent understands that by signing this Stipulation, Respondent voluntarily and knowingly waives the following rights:

- the right to a hearing on the allegations against Respondent, at which time the State has the burden of proving those allegations by a preponderance of the evidence;
- the right to confront and cross-examine the witnesses against Respondent;
- the right to call witnesses on Respondent's behalf and to compel their attendance by subpoena;
- the right to testify on Respondent's own behalf;
- the right to file objections to any proposed decision and to present briefs or oral arguments to the officials who are to render the final decision;
- the right to petition for rehearing; and
- all other applicable rights afforded to Respondent under the United States Constitution, the Wisconsin Constitution, the Wisconsin Statutes, the Wisconsin Administrative Code, and other provisions of state or federal law.

3. Respondent is aware of Respondent's right to seek legal representation and has been provided an opportunity to obtain legal counsel before signing this Stipulation. Respondent is represented by Attorney Mark E. Larson.


4. Respondent agrees to the adoption of the attached Final Decision and Order by the Wisconsin Board of Nursing (Board). The parties to the Stipulation consent to the entry of the attached Final Decision and Order without further notice, pleading, appearance or consent of the parties. Respondent waives all rights to any appeal of the Board's order, if adopted in the form as attached.

5. If the terms of this Stipulation are not acceptable to the Board, the parties shall not be bound by the contents of this Stipulation, and the matter shall then be returned to the Division of Legal Services and Compliance for further proceedings. In the event that the Stipulation is not accepted by the Board, the parties agree not to contend that the Board has been prejudiced or biased in any manner by the consideration of this attempted resolution.

6. The parties to this Stipulation agree that the attorney or other agent for the Division of Legal Services and Compliance and any member of the Board ever assigned as an advisor in this investigation may appear before the Board in open or closed session, without the presence of Respondent or Respondent's attorney, for purposes of speaking in support of this agreement and answering questions that any member of the Board may have in connection with deliberations on the Stipulation. Additionally, any such advisor may vote on whether the Board should accept this Stipulation and issue the attached Final Decision and Order.

7. Respondent is informed that should the Board adopt this Stipulation, the Board's Final Decision and Order is a public record and will be published in accordance with standard Department procedure.

8. The Division of Legal Services and Compliance joins Respondent in recommending the Board adopt this Stipulation and issue the attached Final Decision and Order.

 AND

Lisa C. Hofschulz, R.N., A.P.N.P., Respondent
6163 Washington Circle
Wauwatosa, WI 53213
License no. 139392-30
Certificate no. 2399-33

Date 4/12/18

Mark Larson, Attorney for Respondent
Gutglass, Erickson, Bonville & Larson S.C.
735 N. Water St., #1400
Milwaukee, WI 53202-4106

Date _____

Amanda L. Florek, Attorney
Department of Safety and Professional Services
Division of Legal Services and Compliance
P.O. Box 7190
Madison, WI 53707-7190

Date _____

5. If the terms of this Stipulation are not acceptable to the Board, the parties shall not be bound by the contents of this Stipulation, and the matter shall then be returned to the Division of Legal Services and Compliance for further proceedings. In the event that the Stipulation is not accepted by the Board, the parties agree not to contend that the Board has been prejudiced or biased in any manner by the consideration of this attempted resolution.


6. The parties to this Stipulation agree that the attorney or other agent for the Division of Legal Services and Compliance and any member of the Board ever assigned as an advisor in this investigation may appear before the Board in open or closed session, without the presence of Respondent or Respondent's attorney, for purposes of speaking in support of this agreement and answering questions that any member of the Board may have in connection with deliberations on the Stipulation. Additionally, any such advisor may vote on whether the Board should accept this Stipulation and issue the attached Final Decision and Order.

7. Respondent is informed that should the Board adopt this Stipulation, the Board's Final Decision and Order is a public record and will be published in accordance with standard Department procedure.


8. The Division of Legal Services and Compliance joins Respondent in recommending the Board adopt this Stipulation and issue the attached Final Decision and Order.

Lisa C. Hofschulz, R.N., A.P.N.P., Respondent
6163 Washington Circle
Wauwatosa, WI 53213
License no. 139392-30
Certificate no. 2399-33


Date




Mark Larson, Attorney for Respondent
Gutglass, Erickson, Bonville & Larson S.C.
735 N. Water St., #1400
Milwaukee, WI 53202-4106



Date



Amanda L. Florek, Attorney
Department of Safety and Professional Services
Division of Legal Services and Compliance
P.O. Box 7190
Madison, WI 53707-7190



Date